EUVIMEDOpdag EUVIMED
Crossref

Long‐Term Outcomes of Patients With HPV+ Unknown Primary Squamous Cell Carcinoma Treated With Transoral Surgery

Thomas F Barrett iD, Adam Boukind iD, Kwasi Enin, Patrik Pipkorn, Paul Zolkind, Richard A Harbison, Jason T Rich, Spencer R Bockover, Anthony J Apicelli, Peter Oppelt, Nikhil Rammohan, Michael J Moravan and 6 more

Otolaryngology–Head and Neck Surgery · 2025

DOI: 10.1002/ohn.70029 ↗

At a glance

Journal article in Otolaryngology–Head and Neck Surgery, 2025. Written by Thomas F Barrett and 17 co-authors. Institution: Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St. Louis, Missouri, USA. Major MEDLINE topics: Carcinoma, Squamous Cell, Neoplasms, Unknown Primary, Papillomavirus Infections, Oropharyngeal Neoplasms. 20 references. Funded by: NCI NIH HHS, NIDCR NIH HHS, Burroughs Wellcome Fund Physician-Scientist Institutional Award.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objective

Transoral surgery with neck dissection and risk‐directed adjuvant therapy for unknown primary HPV‐associated squamous cell carcinoma is an effective strategy to identify the primary lesion, minimize radiation dose to the pharynx, and obviate the need for chemotherapy and/or radiation, but late survival outcomes and the development of second primary head and neck (HN) mucosal primaries have not been well described. Study Design Retrospective cohort study of HPV associated unknown primary oropharynx cancer treated with transoral surgery between 2001 and 2012 was performed.

Setting

Academic medical center.

Methods

Demographics, smoking history, staging, adjuvant therapy, disease status, and salvage therapy were reviewed. Kaplan‐Meier estimates for disease‐free, disease‐specific, and overall survival were calculated. Second HN primaries were defined as mucosal lesions that were not HPV‐associated, HPV‐associated at a different subsite, or emerging 5 or more years after treatment.

Results

With a median follow‐up for overall survival calculations of 13.0 years, overall survival, disease‐specific, and disease‐free survival estimates at 10 years were 87.7% (95% CI 79.9%‐96.7%), 96.7% (92.2%‐100%), and 91.7% (84.9%‐99.0%), respectively. Of 15 deaths, only 2 were definitely related to the original cancer. Four patients had a recurrence within 5 years. Seven patients (10.9%) developed a second primary in the head and neck a mean 9.23 years after initial treatment, 3 of which were HPV+.

Conclusion

Long‐term overall, disease‐specific, and disease‐free survival for patients with HPV+ unknown primary carcinomas treated with transoral surgery, neck dissection, and risk‐directed adjuvant therapy are excellent. A minority will develop second primaries HN cancers.

Subjects

MeSH terms (MEDLINE)

Carcinoma, Squamous CellNeoplasms, Unknown PrimaryPapillomavirus InfectionsOropharyngeal NeoplasmsHumansMaleRetrospective StudiesFemaleMiddle AgedAgedNeck DissectionTreatment OutcomeAdultDisease-Free SurvivalSurvival Rate

Author keywords

HPVdeintensificationtransoral surgeryunknown primary

Authors and institutions

  • Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Robert Ebert and Greg Stubblefield Head and Neck Tumor Center at the Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Division of Medical Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Department of Genetics, Washington University School of Medicine, St. Louis, Missouri, USA.

ORCID profiles: Thomas F Barrett, Adam Boukind, Ryan S Jackson

Funding

  • NCI NIH HHS
  • NIDCR NIH HHS
  • Burroughs Wellcome Fund Physician-Scientist Institutional Award

Cite

APA

Barrett, T. F., Boukind, A., Enin, K., Pipkorn, P., Zolkind, P., Harbison, R. A., Rich, J. T., Bockover, S. R., Apicelli, A. J., Oppelt, P., Rammohan, N., Moravan, M. J., Los Santos, J., Gay, H., Adkins, D. R., Thorstad, W. L., Puram, S. V., & Jackson, R. S. (2025). Long‐Term Outcomes of Patients With HPV+ Unknown Primary Squamous Cell Carcinoma Treated With Transoral Surgery. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.70029

Vancouver

Barrett TF, Boukind A, Enin K, Pipkorn P, Zolkind P, Harbison RA, et al. Long‐Term Outcomes of Patients With HPV+ Unknown Primary Squamous Cell Carcinoma Treated With Transoral Surgery. Otolaryngology–Head and Neck Surgery. 2025. doi:10.1002/ohn.70029

BibTeX
@article{Barrett2025,
  author = {Barrett, Thomas F and Boukind, Adam and Enin, Kwasi and Pipkorn, Patrik and Zolkind, Paul and Harbison, Richard A and Rich, Jason T and Bockover, Spencer R and Apicelli, Anthony J and Oppelt, Peter and Rammohan, Nikhil and Moravan, Michael J and Los Santos, Jennifer De and Gay, Hiram and Adkins, Douglas R and Thorstad, Wade L and Puram, Sidharth V and Jackson, Ryan S},
  title = {Long‐Term Outcomes of Patients With HPV+ Unknown Primary Squamous Cell Carcinoma Treated With Transoral Surgery},
  journal = {Otolaryngology–Head and Neck Surgery},
  year = {2025},
  doi = {10.1002/ohn.70029}
}
Start for free →